You just read:

Cantex Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Development for CX-02 in Recurrent Glioblastoma

News provided by

Cantex Pharmaceuticals, Inc.

May 01, 2017, 08:05 ET